Education
About Us
Working with TipRanks
Follow Us
Silence Therapeutics (SLN)
NASDAQ:SLN
SLN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.19 - $24.38
Previous CloseN/A
Volume50.54K
Average Volume (3M)186.48K
Market Cap
$160.51M
Enterprise Value$682.83M
Total Cash (Recent Filing)£121.33M
Total Debt (Recent Filing)£117.00K
Price to Earnings (P/E)―
Beta0.55
Next Earnings
May 14, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.67
Shares Outstanding46,659,940
10 Day Avg. Volume203,466
30 Day Avg. Volume186,478
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.19
Price to Cash Flow (P/CF)-5.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$35.80Price Target Upside940.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Silence Therapeutics News
PremiumCompany Announcements
Silence Therapeutics Plc Earnings Call Highlights Progress and Challenges
PremiumCompany Announcements
Silence Therapeutics Reports 2024 Financial Results and Strategic Focus
PremiumCompany Announcements
Silence Therapeutics Extends Cash Runway to 2027
---
Bulls Say, Bears Say
Bulls Say
Commercial OpportunityZerlasiran's ~100% Lp(a) reduction in clinic, coupled with low dosing frequency and clean safety profile can render a significant commercial opportunity.
Financial FlexibilitySilence's cash runway now extends into 2027, providing financial flexibility to advance its RNAi pipeline in rare diseases.
Regulatory ValidationZerlasiran represents a potential blockbuster opportunity, particularly with regulatory validation from the FDA (U.S.), EMA (Europe), and PMDA (Japan) on the pivotal trial design.
Bears Say
Partnership DelayThe PhIII start for the Lp(a) program is now paused until a partner is secured.
Stock WeaknessThe lack of a clear registrational trial design and the delay of a competitor catalyst from NVS/IONS have contributed to the stock weakness.
---
Ownership Overview
6.10%
Insiders
1.46% Mutual Funds
37.78% Other Institutional Investors
54.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SLN FAQ
What was Silence Therapeutics’s price range in the past 12 months?
Silence Therapeutics lowest stock price was $3.19 and its highest was $24.38 in the past 12 months.
What is Silence Therapeutics’s market cap?
Silence Therapeutics’s market cap is $160.51M.
When is Silence Therapeutics’s upcoming earnings report date?
Silence Therapeutics’s upcoming earnings report date is May 14, 2025 which is in 44 days.
How were Silence Therapeutics’s earnings last quarter?
Silence Therapeutics released its earnings results on Feb 27, 2025. The company reported $0.071 earnings per share for the quarter, beating the consensus estimate of -$0.218 by $0.289.
Is Silence Therapeutics overvalued?
According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued.
Does Silence Therapeutics pay dividends?
Silence Therapeutics does not currently pay dividends.
What is Silence Therapeutics’s EPS estimate?
Silence Therapeutics’s EPS estimate is -0.15.
How many shares outstanding does Silence Therapeutics have?
Silence Therapeutics has 46,659,940 shares outstanding.
What happened to Silence Therapeutics’s price movement after its last earnings report?
Silence Therapeutics reported an EPS of $0.071 in its last earnings report, beating expectations of -$0.218. Following the earnings report the stock price went down -1.048%.
Which hedge fund is a major shareholder of Silence Therapeutics?
Currently, no hedge funds are holding shares in SLN
---
Silence Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.80 (940.70% Upside)
$35.80 (940.70% Upside)
Blogger Sentiment
Bullish
SLN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 295.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.07%
12-Months-Change
Fundamentals
Return on Equity
-99.23%
Trailing 12-Months
Asset Growth
90.06%
Trailing 12-Months
Company Description
Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
---
SLN Company Deck
---
SLN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted positive clinical trial results for zerlasiran and divesiran, revenue growth, and an extended cash runway. However, the termination of the Hansoh Pharma collaboration and the delay of the zerlasiran Phase 3 study due to the need for a partner were significant challenges mentioned.Read More>---
SLN Stock 12 Month Forecast
Average Price Target
$35.80
▲(940.70% Upside)
Technical Analysis
Best Analysts Covering SLN
1 Year
1 Year Success Rate
4/11 ratings generated profit
1 Year Average Return
-15.85%
reiterated a buy rating last month
Copying Myles Minter's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -15.85% per trade.
---